The association between allergy and risk of brain tumors: Evidence from 40 observational studies
-
By
-
Zhihua Pan
-
Senxin Zhang
-
Siyi Cen
-
Chongxian Hou
-
Maoxiang Li
-
Jing’an Ye
-
Jiliang Hu
-
April 21, 2025
-
Clinical Scorecard: Exploring the Link Between Allergic Conditions and Brain Tumor Risk: Insights from 40 Observational Studies
At a Glance
| Category | Detail |
|---|
| Condition | Brain tumors including glioma, meningioma, and acoustic neuroma |
| Key Mechanisms | Inverse association between history of allergic conditions and brain tumor risk |
| Target Population | Individuals with or without history of allergic conditions (hay fever, eczema, asthma, etc.) |
| Care Setting | Epidemiological and clinical research settings; potential implications for risk assessment |
Key Highlights
- Meta-analysis of 40 observational studies including 31 case–control and 9 cohort studies.
- History of allergy associated with decreased brain tumor risk (OR 0.78, 95% CI 0.71–0.86).
- Reduced risk observed in case–control studies but not significantly in cohort studies.
Guideline-Based Recommendations
Diagnosis
- Consider patient history of allergic conditions when assessing brain tumor risk in epidemiological studies.
Management
- No direct management changes recommended based on allergy status; findings are observational.
Monitoring & Follow-up
- Further monitoring and research recommended to clarify allergy-brain tumor risk relationship, especially in cohort populations.
Risks
- No increased brain tumor risk identified in patients with allergic conditions; inverse association suggested.
Patient & Prescribing Data
Patients with history of allergic conditions evaluated for brain tumor risk
No treatment implications established; findings support epidemiological risk assessment only.
Clinical Best Practices
- Use comprehensive patient allergy history in brain tumor risk assessment studies.
- Apply rigorous study design and quality assessment tools (e.g., Newcastle Ottawa Scale) in research.
- Interpret inverse association cautiously, noting differences between case–control and cohort study results.
References
